#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteochondrodysplasia Krabbe's disease Cystic fibrosis lung Interstitial lung disease Acquired C1 inhibitor deficiency Pulmonary tuberculosis Thalassaemia alpha Skin cancer Breast angiosarcoma metastatic Neovascular age-related macular degeneration Osteopetrosis Philadelphia positive acute lymphocytic leukaemia Skin angiosarcoma Arteriosclerosis Cutaneous calcification More trials…

    Learn about Rare Diseases

    Chordoma – Life with Disease Piriformis syndrome Focal segmental glomerulosclerosis – Basic Information Glomerulonephritis rapidly progressive – Life with Disease Marginal zone lymphoma – Diagnostics Systemic sclerosis pulmonary – Diagnostics Haemophilia A with anti factor VIII – Treatment Ehlers-Danlos syndrome – Life with Disease Hypereosinophilic syndrome – Basic Information Mitochondrial myopathy – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    MALIC ACID Sodium Glycerophosphate Florquinitau (18F) SODIUM SULFIDE NONAHYDRATE Pacritinib Rhh646 ICEF15 Esketamine Hydrochloride Nepafenac Nitric Oxide Prasugrel Hydrobromide Bendamustine Hydrochloride Batoclimab ALE.P03 Sodium Oxybate Temsirolimus Fluorouracil VENT-03 Repotrectinib Glucocorticoids More therapies…

    Learn about Your Condition

    Retinopathy of prematurity Adrenoleukodystrophy Eczema Conjunctivitis Lymphoedema Acarodermatitis Oesophageal achalasia Osteosarcoma metastatic Dermatitis atopic Muscular dystrophy Habitual abortion Streptococcal infection Rectosigmoid cancer Rectal cancer stage II Neonatal asphyxia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

    Recruiting

    4 1 1
    Investigated Drugs:
    • Annamycin
    • Cytarabine
    Belgium Czechia France Germany Italy Lithuania +3

  • Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Austria Belgium Czechia France Germany Italy +6

  • Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Venetoclax
    • Azacitidine
    • Ivosidenib
    Austria Belgium Denmark Estonia Finland France +8

  • Study on the Safety and Effects of Lutetium Lu-177 and ABY-271 in Patients with HER2-Positive Metastatic Breast Cancer

    Recruiting

    1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • ABY-271
    • LUTETIUM LU-177
    Belgium France Germany Norway Sweden

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Degarelix
    • Leuprorelin Acetate
    • Relugolix
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Amivantamab
    • Bevacizumab
    • Cetuximab
    Belgium France Germany Hungary Italy The Netherlands +4

  • Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Pembrolizumab
    Belgium France

  • Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Revumenib
    • Venetoclax
    • Azacitidine
    Austria Belgium Denmark Estonia Finland France +8

  • Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Elacestrant
    • Exemestane
    Austria Belgium Czechia Denmark Finland France +9

  • Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • OLVEREMBATINIB
    • Bosutinib
    Belgium France Germany Italy Poland Spain
Previous Page
1 … 3 4 5 6 7 … 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!